Pfizer and BioNTech Close in COVID-19 Vaccine With This Next Big Step
Pfizer and BioNTech made another big step in their fight against COVID-19 by initiating their late-stage study for their lead mRNA vaccine candidate.
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
Pfizer Inc. (NYSE: PFE | PFE Price Prediction) and BioNTech S.E. (NASDAQ: BNTX) made another big step in their fight against COVID-19 by initiating their late-stage study for their lead mRNA vaccine candidate. This trial will be testing the safety and efficacy with up to 30,000 participants around the world.
In terms of the specifics, the Phase 2/3 safety and efficacy clinical study will evaluate a single nucleoside-modified messenger RNA candidate from the BNT162 mRNA-based vaccine program, against SARS-CoV-2.
After review of the preclinical and clinical data from the Phase 1/2 clinical trial and consulting with the U.S. Food and Drug Administration (FDA), among other global regulators, Pfizer and BioNTech are advancing their BNT162b2 vaccine candidate. Note that BNT162b2 recently received Fast Track designation from the FDA. BNT162b2 encodes an optimized SARS-CoV-2 full-length spike glycoprotein, which is the target of virus-neutralizing antibodies.
The companies selected BNT162b2 as the lead candidate for this Phase 2/3 trial upon evaluation of the totality of the data generated so far. Management said that this decision reflects the primary goal to bring a well-tolerated, highly effective vaccine to the market as quickly as possible.
[nativounit]
Pfizer and BioNTech will continue to evaluate their other vaccine candidates as part of a differentiated COVID-19 vaccine portfolio
Pfizer stock closed Monday at $37.54, in a 52-week range of $27.88 to $43.00. The consensus price target is $40.25. The stock was up about 2.8% at $38.61 in early trading indications Tuesday.
BioNTech stock recently closed at $86.53 and has a 52-week range of $12.52 to $105.00. Analysts have a consensus price target of $62.08. The stock was up 2.6% at $88.80 in early indications Tuesday.
[recirclink id=725962][wallst_email_signup]
Contact [email protected] for any questions or corrections.
Chris Lange is a financial and geopolitical writer with more than a decade of experience covering a myriad of topics. He has published thousands of articles for 24/7 Wall St., with past coverage focused heavily on stocks, IPOs, healthcare, defense, global affairs, and technology.
His work has been quoted, or referenced by a number of outlets including Business Insider, USA Today, Yahoo Finance, MSN, The Motley Fool, and many other publications. A graduate of Southwestern University, he studied business with a focus on investments and has previous experience in banking and startups.
When not reading or writing the news, he is following his passion for Lacrosse, playing chess, or building solar projects with his dad.
